Recombinant Human VEGF-D Protein, His Tag_C230253

Description

Vascular endothelial growth factor D (VEGF-D), also known as c-fos-induced growth factor (FIGF), is a secreted glycoprotein of the VEGF/PDGF family. VEGFs regulate angiogenesis and lymphangiogenesis during development and tumor growth, and are 
characterized by eight conserved cysteine residues that form a cystine knot structure. VEGF-C and VEGF-D, which share 23% amino acid (aa) sequence identity, are uniquely expressed as preproproteins that contain long N- and C-terminal propeptide extensions
around the VEGF homology domain (VHD). Proteolytic processing of the 354 aa VEGF-D preproprotein creates a secreted proprotein. Further processing by extracellular serine proteases, such as plasmin or furin-like proprotein convertases, forms mature VEGF-D consisting of non- covalently linked 42 kDa homodimers of the 117 aa VHD. Mature human VEGF-D shares 94%, 95%, 99%, 97% and 93% aa identity with mouse, rat, equine, canine and bovine VEGF-D, respectively. It is expressed in adult lung, heart, 
muscle, and small intestine, and is most abundantly expressed in fetal lungs and skin. Mouse and human VEGF-D are ligands for VEGF Receptor 3 (VEGF R3, also called Flt-4) that are active across species and show enhanced affinity when processed. Processed
human VEGF-D is also a ligand for VEGF R2, also called Flk-1 or KDR. VEGF R3 is strongly expressed in lymphatic endothelial cells and is essential for regulation of the growth and differentiation of lymphatic endothelium. While VEGF-C is the critical ligand
for VEGF R3 during embryonic lymphatic development, VEGF-D is most active in neonatal lymphatic maturation and bone growth. Both promote tumor lymphangiogenesis . 

Product Properties

Synonyms

c-fos induced growth factor (vascular endothelial growth factor D); FIGF; vascular endothelial growth factor D; VEGFD; VEGF-D; VEGF-DVEGFDc-Fos-induced growth factor
Accession

O43915

Source
HEK293 Cells-derived human VEGFD, Phe 93-Ser 201 with His tag at the C-terminu

Molecular Weight

The recombinant mature form of human VEGFD consists of 120 amino acids and has a predicted molecular mass of 13.6 kDa. In SDS-PAGE under reducing conditions, it migrates with an apparent molecular mass of 20-22 kDa due to glycosylation.
Tag
His

Purity

> 95% by SDS-PAGE.
Biological Activity
Measured in a cell proliferation assay using human umbilical vein endothelial cells (HUVEC). The ED50 for this effect is 0.3- 1.6 μg/mL

Endotoxin

< 1.0 EU per 1μg of the protein by the LAL method.
Concentration
0.95 mg/mL
Formulation
Lyophilized from a 0.2 μm filtered concentrated solution in PBS, pH 7.4.
Reconstitution
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20°C. Further dilutions should be made in appropriate buffered solutions.

 

Shipping and Storage

The products are shipped with ice pack and can be stored at -20 ℃ for 1 year.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
3 months, -20 °C under sterile conditions after reconstitution.
Recommend to aliquot the protein into smaller quantities when first used and avoid repeated freeze-thaw cycles.

Cautions

1. Avoid repeated freeze-thaw cycles.
2. For your safety and health, please wear lab coats and disposable gloves for operation.
3. For research use only

Recombinant Human VEGF-D Protein, His Tag_C230253

Product form

SKU: C230253E

$179.00

      • Tell a unique detail about this product

      Description

      Vascular endothelial growth factor D (VEGF-D), also known as c-fos-induced growth factor (FIGF), is a secreted glycoprotein of the VEGF/PDGF family. VEGFs regulate angiogenesis and lymphangiogenesis during development and tumor growth, and are 
      characterized by eight conserved cysteine residues that form a cystine knot structure. VEGF-C and VEGF-D, which share 23% amino acid (aa) sequence identity, are uniquely expressed as preproproteins that contain long N- and C-terminal propeptide extensions
      around the VEGF homology domain (VHD). Proteolytic processing of the 354 aa VEGF-D preproprotein creates a secreted proprotein. Further processing by extracellular serine proteases, such as plasmin or furin-like proprotein convertases, forms mature VEGF-D consisting of non- covalently linked 42 kDa homodimers of the 117 aa VHD. Mature human VEGF-D shares 94%, 95%, 99%, 97% and 93% aa identity with mouse, rat, equine, canine and bovine VEGF-D, respectively. It is expressed in adult lung, heart, 
      muscle, and small intestine, and is most abundantly expressed in fetal lungs and skin. Mouse and human VEGF-D are ligands for VEGF Receptor 3 (VEGF R3, also called Flt-4) that are active across species and show enhanced affinity when processed. Processed
      human VEGF-D is also a ligand for VEGF R2, also called Flk-1 or KDR. VEGF R3 is strongly expressed in lymphatic endothelial cells and is essential for regulation of the growth and differentiation of lymphatic endothelium. While VEGF-C is the critical ligand
      for VEGF R3 during embryonic lymphatic development, VEGF-D is most active in neonatal lymphatic maturation and bone growth. Both promote tumor lymphangiogenesis . 

      Product Properties

      Synonyms

      c-fos induced growth factor (vascular endothelial growth factor D); FIGF; vascular endothelial growth factor D; VEGFD; VEGF-D; VEGF-DVEGFDc-Fos-induced growth factor
      Accession

      O43915

      Source
      HEK293 Cells-derived human VEGFD, Phe 93-Ser 201 with His tag at the C-terminu

      Molecular Weight

      The recombinant mature form of human VEGFD consists of 120 amino acids and has a predicted molecular mass of 13.6 kDa. In SDS-PAGE under reducing conditions, it migrates with an apparent molecular mass of 20-22 kDa due to glycosylation.
      Tag
      His

      Purity

      > 95% by SDS-PAGE.
      Biological Activity
      Measured in a cell proliferation assay using human umbilical vein endothelial cells (HUVEC). The ED50 for this effect is 0.3- 1.6 μg/mL

      Endotoxin

      < 1.0 EU per 1μg of the protein by the LAL method.
      Concentration
      0.95 mg/mL
      Formulation
      Lyophilized from a 0.2 μm filtered concentrated solution in PBS, pH 7.4.
      Reconstitution
      We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20°C. Further dilutions should be made in appropriate buffered solutions.

       

      Shipping and Storage

      The products are shipped with ice pack and can be stored at -20 ℃ for 1 year.
      1 month, 2 to 8 °C under sterile conditions after reconstitution.
      3 months, -20 °C under sterile conditions after reconstitution.
      Recommend to aliquot the protein into smaller quantities when first used and avoid repeated freeze-thaw cycles.

      Cautions

      1. Avoid repeated freeze-thaw cycles.
      2. For your safety and health, please wear lab coats and disposable gloves for operation.
      3. For research use only

      © 2024 Arcegen, Powered by Shopify

      • American Express
      • Apple Pay
      • Diners Club
      • Discover
      • Meta Pay
      • Google Pay
      • Mastercard
      • Shop Pay
      • Visa

      Login

      Forgot your password?

      Don't have an account yet?
      Create account